ArticleFrontiers in oncology2026
An integrated body composition- immunonutritional signature for predicting immunotherapy response and prognosis in gastric cancer: a multicenter retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Response to neoadjuvant PD-1 inhibitor plus chemotherapy in locally advanced esophagogastric adenocarcinoma varies widely, and tumor biomarkers alone do not fully explain the variation. We developed an integrated Body Composition and Immunonutritional Signature (BCIS) from pretreatment CT body composition and routine blood markers, and tested whether it predicts pathological response, immune-related adverse events (irAEs), and survival. Methods: From four tertiary hospitals in Hebei Province, China, we enrolled 720 patients with histologically confirmed gastric or gastroesophageal junction (Siewert II/III) adenocarcinoma treated between 2019 and 2023 with neoadjuvant PD-1 inhibitor plus SOX or XELOX followed by D2 gastrectomy. BCIS was a 0-10 additive score from ten prespecified adverse host features. Analyses included logistic regression, restricted cubic spline (RCS) modeling, multivariable Cox regression, DeLong tests for nested AUC comparisons, decision-curve analysis, eleven sensitivity scenarios, and collinearity checks by Spearman correlation and variance inflation factors. Results: BCIS classified 243 (33.8%) patients as favorable, 303 (42.1%) as intermediate, and 174 (24.2%) as unfavorable. Major pathological response (MPR) rates dropped sharply across strata (64.2%, 39.6%, 21.8%; P-trend<0.001). After adjusting for age, sex, cT/cN, PD-L1 CPS, MMR status, EGJ origin, and regimen, every BCIS point cut the odds of MPR by roughly 40% (adjusted OR = 0.61, 95% CI 0.55-0.68, P<0.001) and pCR by close to half (adjusted OR = 0.55, 95% CI 0.46-0.66, P<0.001). RCS modeling flagged CRP and CAR as nonlinear; BCIS itself was strictly linear. Adding BCIS to a clinical baseline lifted overall AUC for MPR from 0.597 to 0.710 (DeLong P<0.001) and external AUC from 0.588 to 0.704. At 42.5 months' median follow-up, each BCIS point raised the hazard of progression by 53% (adjusted HR = 1.53, 95% CI 1.44-1.63) and of death by 38% (adjusted HR = 1.38, 95% CI 1.29-1.47; both P<0.001). Direction of effect held across every prespecified subgroup (P-interaction>0.10 throughout) and all eleven sensitivity scenarios. Conclusions: BCIS is independently associated with pathological response and survival under neoadjuvant PD-1-based immunochemotherapy and adds discrimination beyond tumor-centered biomarkers and clinical staging. Because every component comes from routine pretreatment workup at no extra cost, BCIS could feasibly inform prehabilitation, toxicity surveillance, and shared decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.